Cargando…
Recent advances in the biology and treatment of B-cell acute lymphoblastic leukemia
Acute lymphoblastic leukemia (ALL) is a hematologic malignancy arising from precursors of the lymphoid lineage. Conventional cytotoxic chemotherapies have resulted in high cure rates of up to 90% in pediatric ALL, but the outcomes for adult patients remain suboptimal with 5-year survival rates of on...
Autores principales: | Hefazi, Mehrdad, Litzow, Mark R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6467350/ https://www.ncbi.nlm.nih.gov/pubmed/31360093 http://dx.doi.org/10.2147/BLCTT.S170351 |
Ejemplares similares
-
Antigen-based immunotherapy for the treatment of acute lymphoblastic leukemia: the emerging role of blinatumomab
por: Litzow, Mark R
Publicado: (2014) -
Recent advances on blinatumomab for acute lymphoblastic leukemia
por: Zhao, Juanjuan, et al.
Publicado: (2019) -
Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives
por: Anagnostou, Theodora, et al.
Publicado: (2017) -
Recent Advances in Treatment Options for Childhood Acute Lymphoblastic Leukemia
por: Malczewska, Marta, et al.
Publicado: (2022) -
Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia
por: Jain, Tania, et al.
Publicado: (2020)